A new oral contraceptive regimen for endometriosis management: preliminary experience with 24/4-day drospirenone/ethinilestradiol 3 mg/20 mcg

By Mabrouk Mohamed   Solfrini Serena   Frascà Clarissa   Del Forno Simona   Montanari Giulia   Ferrini Giulia   Paradisi Roberto   Seracchioli Renato  

Gynecological Endocrinology, Vol. 28, Iss. 6, 2012-06 ,pp. : 451-454

Informa Healthcare

Access to resources Recommend Favorite

User Experience with an Oral Contraceptive Containing Ethinylestradiol 30g and Drospirenone 3mg (Yasmin ® ) in Clinical Practice

By Schultz-Zehden Beate  

Treatments in Endocrinology, Vol. 5, Iss. 4, 2006-01 ,pp. : 251-256

Adis International

Access to resources Recommend Favorite

Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 g ethinylestradiol and 150 g levonorgestrel: a randomized trial

By Oddsson K.  

Human Reproduction, Vol. 20, Iss. 2, 2005-02 ,pp. : 557-562

Oxford University Press

Access to resources Recommend Favorite

Comparison of a 24-day and a 21-day pill regimen for the novel combined oral contraceptive, nomegestrol acetate and 17β-estradiol (NOMAC/E 2 ): a double-blind, randomized study

By Christin-Maitre S.   Serfaty D.   Chabbert-Buffet N.   Ochsenbein E.   Chassard D.   Thomas J.-L.  

Human Reproduction, Vol. 26, Iss. 6, 2011-06 ,pp. : 1338-1347

Oxford University Press

Access to resources Recommend Favorite

Ethinylestradiol/Drospirenone: A Review of its Use as an Oral Contraceptive

By Keam S.J.   Wagstaff A.J.  

Treatments in Endocrinology, Vol. 2, Iss. 1, 2003-01 ,pp. : 39-61

Adis International

Access to resources Recommend Favorite